Quality of Clinician-Reported Cancer History When Ordering Genetic Testing
- 24 July 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 2 (2), 1-11
- https://doi.org/10.1200/CCI.18.00014
Abstract
Purpose Clinical history data reported on test requisition forms (TRFs) for hereditary cancer multigene panel testing (MGPT) are routinely used by genetic testing laboratories. More recently, publications have incorporated TRF-based clinical data into studies exploring yield of testing by phenotype and estimating cancer risks for mutation carriers. We aimed to assess the quality of TRF data for patients undergoing MGPT. Patients and Methods Ten percent of patients who underwent hereditary cancer MGPT between January and June 2015 at a clinical laboratory were randomly selected. TRF-reported cancer diagnoses were evaluated for completeness and accuracy for probands and relatives using clinical documents such as pedigrees and chart notes as the comparison standard in cases where these documents were submitted after the time of test order. Results TRF-reported cancer sites and ages at diagnosis were complete for > 90.0% of proband cancer diagnoses overall, and the completion rate was even higher (> 96.0%) for breast, ovarian, colorectal, and uterine cancers. When reported, these data were accurate on TRFs for > 99.5% of proband cancer sites and > 97.5% of proband ages at diagnosis. Cancer site and age at diagnosis data were also complete on the TRF for the majority of cancers among first- and second-degree relatives. Completeness decreased as relation to the proband became more distant, whereas accuracy remained high across all degrees of relation. Conclusion Data collected as part of cancer genetic risk assessment is completely and accurately reported on TRFs for the majority of probands and their close relatives and is comparable to information directly obtained from clinic notes, particularly for breast and other cancers commonly associated with hereditary cancer syndromes. (C) 2018 by American Society of Clinical OncologyThis publication has 19 references indexed in Scilit:
- Gene-Panel Sequencing and the Prediction of Breast-Cancer RiskNew England Journal of Medicine, 2015
- Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriersJournal of Medical Genetics, 2015
- GermlineTP53Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family RegistryJAMA Oncology, 2015
- Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2Gynecologic Oncology, 2015
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panelCancer, 2014
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk AssessmentJournal of Clinical Oncology, 2014
- Genetic counselor review of genetic test orders in a reference laboratory reduces unnecessary testingAmerican Journal of Medical Genetics Part A, 2014
- Panel‐based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratoryClinical Genetics, 2014
- Bias in the Reporting of Family History: Implications for Clinical CareJournal of Genetic Counseling, 2012
- The Comprehensiveness of Family Cancer History Assessments in Primary CarePublic Health Genomics, 2007